Table 2 Evidence from the studies included in the systematic review concerning the sex-related differences in the effectiveness of asthma treatments
From: Sex differences in adult asthma and COPD therapy: a systematic review
Outcomes | Treatments and comparisons | ||||
|---|---|---|---|---|---|
ICS | SABA | ICS/LABA/LAMA | Omalizumab | Mepolizumab | |
vs. PCB or baseline | vs. baseline | vs. ICS/LABA | vs. PCB or baseline | vs. PCB | |
FEV1 | [33]: men responded significantly better than women | [34]: women ≈ men | / | / | |
FEV1/FVC | / | [36]: women responded significantly better than men | / | / | / |
Protection against bronchial provocation | [31]: men responded significantly better than women | / | / | / | / |
Exacerbation | [32]: borderdline significance only in men | / | [34]: women ≈ men | [39]: women ≈ men | / |
Time to first episode of asthma worsening | / | / | [34]: women ≈ men | / | / |
Asthma control | [32]: men responded significantly better than women | / | / | [37]: women ≈ men | [38]: women responded significantly better than men |
Asthma symptoms | [32]: men responded significantly better than women | / | / | / | / |
Asthma perception | / | / | / | [37]: men responded significantly better than women | / |
Quality of life | / | / | / | [37]: men responded significantly better than women | / |
FeNO | / | [36]: significantly greater in women than men | / | / | / |